Thymosin beta-4 is the full endogenous protein behind the popular "TB-500"
research product. Reading this monograph alongside the TB-500 monograph is the
best way to understand the difference.
Chemical identity & structure.
Thymosin beta-4 (TB4) is a 43-amino-acid protein found widely in human cells and
fluids. It is one of the most abundant intracellular proteins involved in actin
regulation. The key distinction for this library: **TB4 is the full natural
protein; "TB-500" is a shorter synthetic fragment-based research product** built
around TB4's actin-binding region. They are related, not interchangeable.
Mechanism of action.
TB4's primary, best-characterized function is sequestering actin monomers —
regulating the pool of actin available for building the cytoskeleton. Through
this role it influences cell migration, a process central to wound healing and
tissue repair. TB4 is also reported to promote angiogenesis, modulate
inflammation, and support cell survival under stress.
Key research findings.
Preclinical research reports roles for TB4 in cardiac repair, wound healing,
corneal and skin repair, and neurological injury models. Unlike the TB-500
fragment, the full TB4 protein has been advanced into some human clinical
research — for example, formulations studied for ophthalmic (eye-surface) and
dermal wound applications.
The research / citation base.
TB4 has a broader and more credible research base than the TB-500 product,
including some human clinical studies for specific applications. It is still not
an approved general therapy, and the systemic-use evidence is far thinner than
the topical/local-application research. Be precise about which molecule —
full TB4 or the TB-500 fragment — any claim refers to.
Human clinical trial data.
In the phase 2 randomized, double-masked trial by Sosne et al. (2015), nine
patients with severe dry eye were treated with Thymosin β4 eye drops (RGN-259,
0.1%) or vehicle control 6 times daily over a period of 28 days
(PubMed). There is no single
validated systemic human protocol.
Quality & sourcing notes.
Because TB4 is a 43-residue protein, verification is more involved than for a
short peptide. A credible COA confirms the full-length sequence by mass
spectrometry and reports HPLC purity. Confirm whether a product is full-length
TB4 or a fragment — the label often blurs this.
*Research-use note: Educational summary of published research. Thymosin beta-4 is
not an approved general therapy; this is research context only, not medical
advice.*
